Market Whales and Their Recent Bets on MRNA Options
Portfolio Pulse from Benzinga Insights
Financial giants have shown a bullish stance on Moderna (NASDAQ:MRNA) through recent options trading, with a mix of bullish and bearish trades observed. The trading activity suggests a target price range of $40.0 to $115.0 for MRNA over the next three months. Moderna, a commercial-stage biotech company, has seen its mRNA technology gain rapid validation, especially with its COVID-19 vaccine. The current trading volume is 2,962,331 with the stock price at $99.48. Analysts have given mixed reviews, with an average target price of $100.67, ranging from $86 to $125.
March 08, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna has seen significant options trading activity, suggesting a bullish sentiment among financial giants, with a predicted price range of $40.0 to $115.0. Analysts have provided mixed ratings, with an average target price of $100.67.
The bullish options trading activity by financial giants indicates a positive outlook on Moderna's stock, potentially driving its price up in the short term. The mixed analyst ratings, with an average target price close to the current trading price, further support the potential for price movement within the predicted range.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100